Clinical trial of cefotaxime in patients with typhoid fever.
In 45 patients in whom typhoid fever was confirmed by culture of a blood sample, cefotaxime (1 gm BID) was administered intravenously for four days; if defervescence did not occur by day 5, the dosage was increased to 2 gm BID until defervescence, when it was reduced to 1 gm BID until discharge. On average, defervescence occurred on day 7 (range, day 3 to day 14), requiring a total dose of 31 gm (range, 12 to 60 gm) of cefotaxime. Relapse, occurring in three patients, was treated with co-trimoxazole. The duration of cefotaxime therapy was longer than therapy with chloramphenicol but without the risk of bone marrow depression.
D000293:Adolescent; D000328:Adult; D000368:Aged; D002439:Cefotaxime / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D012485:Salmonella typhi / Q000302:isolation & purification; D013997:Time Factors; D014435:Typhoid Fever / Q000188:drug therapy* / Q000382:microbiology
D002439:Cefotaxime